Nasdaq
Anbio Biotechnology Prices $8M IPO
The firm plans to use the proceeds to support its commercialization and R&D activities as well as for working capital and general corporate purposes.
T2 Biosystems Lays off Employees, Inks Consulting Agreements With Top Execs
Following a delisting decision by the Nasdaq Hearings Panel, the firm laid off its workforce and agreed to pay top executives for part-time consulting work.
Nasdaq Panel Delisting T2 Biosystems Stock
The company was in violation of the stock exchange's requirements for the minimum bid price and the market value of listed securities.
IVD Firm Anbio Biotechnology Files for IPO
The German IVD developer said that it plans to offer 1.6 million shares on the Nasdaq Global Market.
Aspira Receives Delisting Notice, Announces Plans to Appeal the Decision
The firm received notice that it had failed to regain compliance with the Nasdaq's requirement to maintain a minimum $35 million market value of listed securities.
Dec 30, 2024
Nasdaq Affirms OpGen's Delisting Decision
Dec 13, 2024
T2 Biosystems Receives Delisting Notice From Nasdaq
Nov 7, 2024
Trinity Biotech Regains Nasdaq Compliance
Oct 15, 2024
Nasdaq to Delist Centogene
Aug 23, 2024
OpGen Shares Suspended From Trading on Nasdaq
Aug 8, 2024
Centogene Delisted From Nasdaq
Aug 1, 2024
360Dx Top 30 Jumps 11 Percent in July
May 16, 2024
OpGen to Execute 1-for-10 Reverse Stock Split
Apr 24, 2024
Nasdaq Warns OpGen About Overdue 2023 Annual Report
Apr 17, 2024
DermTech Receives Delisting Warning From Nasdaq
Mar 1, 2024